News | September 03, 2023
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Fluorouracil Injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum and breast
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
